newsfilter
← Latest News
GlobeNewswire·

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

Initiated a second potentially registrational study of IMVT-1402 in Graves' disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren's disease (SjD), both in June 2025All other clinical trials in